Noticias y eventos de China SXT Pharmaceuticals Inc (SXTC)SXTCChina SXT Pharmaceuticals Inc

China SXT Pharmaceuticals Terminates Direct Offering Agreement

China SXT Pharmaceuticals announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026. Under the termination letter agreement, the company and the purchasers have terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement entered into in connection with the Offering. The terminated right had permitted the purchasers, during the 30-day period following the closing of the Offering, to elect to purchase up to an additional $12M of Class A ordinary shares and/or pre-funded warrants on the same terms and conditions as the Offering. As a result of the termination, the purchasers no longer have any right, claim or entitlement to make an additional purchase under Section 2.4 of the securities purchase agreement. All other provisions of the securities purchase agreement and the other transaction documents remain unchanged and in full force and effect. The termination does not affect the securities issued in the Offering.

China SXT Pharmaceuticals Enters Agreement to Issue 8M Shares

China SXT Pharmaceuticals announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 8M Class A ordinary shares of the company, no par value per share at a purchase price of $1.50 per share in a registered direct offering. The company also agreed to issue to the same investors 8M warrants with an exercise price of $1.50 per share. The Warrants will be immediately exercisable upon issuance and have a 1-year term from the date of issuance. Each warrant has a zero cash exercise option permitting the holder to acquire up to 9 Class A shares. The aggregate gross proceeds to the company of this offering are expected to be approximately $12M, before deducting placement agent fees and other offering expenses payable by the company. Investors will have an additional purchase right to acquire up to $12M of securities on the same terms and conditions during the 30-day period after closing. The offering is expected to close on or about October 9, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.

China SXT Pharmaceuticals Issues 4.5M Units at $2.00 Each

China SXT Pharmaceuticals announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4.5M units, consisting of one Class A ordinary share of the company and one common warrant at a purchase price of $2.00 per Unit in a registered direct offering. Each of the Warrants will have an exercise price of $3.20 per Class A Class A ordinary share, will be immediately exercisable upon issuance, and will expire on the one year anniversary of the issuance date. The aggregate gross proceeds to the company of this offering are expected to be approximately $9M, before deducting placement agent fees and other offering expenses payable by the company. The transaction is expected to close on or about July 24, subject to the satisfaction of customary closing conditions. Univest Securities is acting as the sole placement agent.